"$35 Insulin Cap Widens Access for Americans as New Policies Take Effect"

In 2024, more Americans with diabetes will benefit from reduced insulin costs as Sanofi joins other major insulin manufacturers in capping prices at $35 for many patients. This follows public pressure and legislative changes, including the Inflation Reduction Act, which caps Medicare insulin costs. The manufacturers are also lowering list prices significantly, partly to avoid increased Medicaid rebate payments due to changes in the American Rescue Plan Act. These price reductions are expected to save the companies hundreds of millions of dollars in rebates while also potentially increasing their profits from Medicaid sales.